Abstract
A novel subretinal Matrigel model of choroidal neovascularization (CNV) was devised, with several unique features that mimic those in human exudative (wet) AMD. With this model and VEGF Trap, a potent receptor-based inhibitor of VEGF-A and PlGF, the data show that inhibition of VEGF-A, and perhaps PlGF as well, not only stops the growth and induces regression of experimental CNV, but also inhibits the associated inflammation and fibrotic responses.
